External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ELCC 2025
Roche and Genentech at

ELCC 2025

March 26 - March 29
Paris, France
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Mar 27 / Roche and Genentech
A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Efficacy and safety from the phase II BO44178 study of tobemstomig plus platinum-based chemotherapy versus pembrolizumab plus chemotherapy in patients with untreated locally advanced or metastatic NSCLC.
Oncology Lung Cancer ELCC-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 24 / Roche and Genentech
IMpower010: Digital pathology (DP) vs manual SP263 PD-L1 tumour cell (TC) scoring on whole imaging slides from patients (pts) with stage II-IIIA PD-L1 TC >=50% NSCLC
PD-L1 expression is predictive of anti–PD-1/–PD-L1 therapy benefit, but intratumoral heterogeneity, interobserver variability, multiple assays and scoring systems make its reliable evaluation problematic. A clone-agnostic artificial intelligence (AI) model for AI-based measurement of PD-L1 (AIM-PD-L1) was developed to address this challenge. In this exploratory analysis, we compared manual and AIM-PD-L1 scoring of SP263-stained tumour cell (TC) PD-L1 to assess the model’s ability to identify patients with stage II-IIIA PD-L1 TC ≥50% NSCLC from IMpower010 who can benefit from atezolizumab (NCT02486718) in an unbiased, automated manner.
Oncology Lung Cancer ELCC-2025
03:25 PM
Duration 5mins Paris
A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Nadal E, Rittmeyer A, de Marinis F, Lee D-H, Gadgeel S, Vilario N, Bria E, Arulananda S, Antic V, Bennett L, Hu Y, Madden-Raja K, Williams P, Prizant H, Popat S
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 45mins Paris, France
IMpower010: Digital pathology (DP) vs manual SP263 PD-L1 tumour cell (TC) scoring on whole imaging slides from patients (pts) with stage II-IIIA PD-L1 TC >=50% NSCLC
Martin Reck, Enriqueta Felip, Nasser Altorki, Heather A. Wakelee, Eric Vallières, Rüdiger Liersch, Satoshi Oizumi, Hiroshi Tanaka, Silvia Novello, Daniel Ruderman, Barzin Nabet, Lauren Brunner, Stephanie Hennek, Barbara Gitlitz, Marcus Ballinger, Elizabeth Bennett, Jennifer M. Giltnane, Minu K. Srivastava, Caicun Zhou
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.